An overview of current therapy options of non-alcoholic fatty liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35728962/
Finding an effective treatment of non-alcoholic fatty liver disease (NAFLD) remains one of main challenges in hepatological research for the 21st century, since there is no such a treatment yet....
Conclusion/Relevance: Current pharmacological treatment of NAFLD comprises screening and therapy of metabolic syndrome components and minimizing of alcohol intake. There are new substances being evaluated in clinical trials, the most promising ones are semaglutide and lanifibranor.
-
Dr Hamid3yr(NAFLD) remains one of main challenges In patients with DM II and obesity
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35737858/
BACKGROUND: The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by...
CONCLUSIONS: As a long-term weight management therapy, semaglutide 2.4 mg was estimated to be cost-effective compared with no treatment, D&E alone, and all other branded AOM comparators under a WTP threshold of $150,000 per QALY gained over a 30-year time horizon.
-
Dr Hamid3yrsemaglutide 2.4 mg was estimated to be cost-effective option for patients
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Leigh Perreault, Melanie Davies, Juan P. Frias, Peter Nørkjaer Laursen, Ildiko Lingvay, Sriram Machineni, Anette Varbo, John P.H. Wilding, Signe Olrik Rytter Wallenstein, Carel W. le Roux; Changes in Glucose...
CONCLUSIONS: STEP 1, 3, and 4 collectively provide a robust assessment of the effects of semaglutide on glucose metabolism and prediabetes in a large cohort of adults with overweight/obesity while on treatment. Among participants with baseline prediabetes, 68 weeks’ treatment with semaglutide versus placebo led to significant improvements in...
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis - International Journal of Clinical Pharmacy
Source : https://link.springer.com/article/10.1007/s11096-022-01428-1
Background Research on semaglutide's effect on weight loss has been largely focused on Type 2 Diabetics. No meta-analyses of semaglutide's efficacy in non-diabetic individuals have been conducted to date. Expanding...
Conclusion: This systematic review and meta-analysis validates the clinical efficacy of semaglutide for the treatment of obesity in the adult, non-diabetic population.
Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35713074/
The availability of newer glucose-lowering drugs has created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors)...
Relevance: We present a clinical perspective to compare and control these two classes of drugs, and promote rational prescription in diabetes praxis.